Navigation Links
Palatin Technologies Announces Third Quarter Fiscal Year 2013 Results and Update on Development of Bremelanotide for Female Sexual Dysfunction
Date:5/14/2013

CRANBURY, N.J., May 14, 2013 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced financial results for the third quarter ended March 31, 2013. The Company also summarized end-of-Phase 2 discussions with the U.S. Food and Drug Administration (FDA) and next steps for its Phase 3 pivotal registration program for bremelanotide, its product in development as a novel treatment for female sexual dysfunction (FSD). Palatin will hold a conference call and live audio webcast later today.

End-of-Phase 2 Meeting with FDA on Bremelanotide for FSD
In the end-of-Phase 2 meeting with FDA, Palatin reached preliminary agreement on key aspects of the Phase 3 pivotal registration studies, including:

  • FSD patient population
  • Primary and key secondary efficacy endpoints
  • Study design
  • Dose selection
  • Safety monitoring
  • In addition, the FDA agreed with Palatin's position that the blood pressure and heart rate signals of bremelanotide had been adequately characterized during the Phase 2 program. The FDA also agreed with the proposed Phase 3 blood pressure monitoring program, which will consist of standardized methods for in-clinic assessment of blood pressure.

    "We view our positive meeting with the FDA as a major milestone in the development of bremelanotide for FSD. We are pleased to have concurrence from the FDA on the design and selection of efficacy endpoints of our Phase 3 clinical studies," stated Carl Spana, Ph.D., President and CEO of Palatin. "We are also pleased with the FDA's concurrence that the blood pressure monitoring program for our Phase 3 clinical studies only includes standardized methods for in-clinic assessment of blood pressure. We look forward to advancing bremelanotide for FSD towards a suc
    '/>"/>

    SOURCE Palatin Technologies, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related biology technology :

    1. Palatin Technologies, Inc. To Report Fiscal Year 2013 Third Quarter Results; Teleconference and Webcast to be held on May 14, 2013
    2. Palatin Technologies Announces Notification of Patent Allowance On Melanocortin Receptor-Specific Peptides for Sexual Dysfunction
    3. Palatin Technologies To Present At The 25th Annual ROTH Conference
    4. Palatin Technologies, Inc. To Present At The Cowen & Company 33rd Annual Health Care Conference
    5. Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2013 Results; Teleconference and Webcast to be held on February 14, 2013
    6. Palatin Technologies, Inc. To Report Fiscal Year 2013 Second Quarter Results; Teleconference and Webcast to be held on February 14, 2013
    7. Palatin Technologies, Inc. to Present at 15th Annual BIO CEO & Investor Conference
    8. Palatin Technologies, Inc. to Present at the 24th Annual Piper Jaffray Healthcare Conference
    9. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2013 Results; Teleconference and Webcast to be held on November 14, 2012
    10. Palatin Technologies, Inc. To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
    11. Palatin Technologies, Inc. To Report Fiscal Year 2013 First Quarter Results; Teleconference and Webcast to be held on November 14, 2012
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/22/2014)... CA (PRWEB) October 22, 2014 ... from Sartorius, A & D Weighing, Rice Lake, ... CPA Semi-Micro Balance . The Sartorius CPA Semi-Micro ... an affordable high-quality, precise, and user-friendly laboratory balance. ... of laboratory equipment, their laboratory balances are well ...
    (Date:10/22/2014)... --  Synthetic Biologics, Inc. (NYSE MKT: SYN), a ... and diseases, announced today that the U.S. Patent and ... a composition of matter patent application that covers the ... This is Synthetic Biologics, first allowed patent application directly ... the Company,s extensive C. difficile patent estate. ...
    (Date:10/22/2014)... and HONG KONG , Oct. 22, ... therapeutics enterprise, announced today that rare disease expert ... vice president, research. Dr. McKew brings more than two ... positions at the National Institutes of Health, Wyeth Research ... Wyeth). Dr. McKew will lead aTyr,s efforts to expand and ...
    (Date:10/20/2014)... , Oct. 20, 2014 Asterias ... the Company has signed a Notice of Grant ... Medicine (CIRM), effective October 1, 2014.  The NGA ... payments and the release of additional grant funds ... grant award for clinical development of Asterias, product, ...
    Breaking Biology Technology:Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 2Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4
    ... Fla., Oct. 7 GeneWize Life Sciences ... Bulletin Board: GNLK) announced before a full house of ... targeting the teen market, adding to their current flagship ... The new nutrition and skin-clearing products, aimed ...
    ... BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ... Executive Officer of BioMarin, will host a ... 28, at 5:00 p.m. ET to discuss ... Dial-in Number:  866.202.3048International Dial-in Number:  617.213.8843Participant Code: ...
    ... JOSEPH, Mich., Oct. 7 GeneGo, Inc., a leading ... and chemistry, announced today that they have integrated GenomeQuest,s ... MetaDrug. Using GenomeQuest,s interactive analysis, scientists who ... of interest (hundreds of millions of reads, to thousands ...
    Cached Biology Technology:GeneWize Announces New Skin Clearing Product and Teen Nutrition at Annual Convention 2BioMarin to Host Third Quarter 2010 Financial Results Conference Call and Webcast on Thursday, October 28 at 5:00 p.m. ET 2GeneGo Announces Integration With GenomeQuest for Pathway Analysis of Next Generation Sequencing Data 2
    (Date:10/17/2014)... critical and pertinent for practicing physicians and clinicians given ... The Journal, Disaster Medicine and Public Health Preparedness ... Public Health, to surround the public, medical professionals and ... , On October 17, the journal published ... was prepared by Dr. Eric Toner, internist and emergency ...
    (Date:10/17/2014)... To date, antidotes ... doctors are often limited to supportive therapy such as induced ... of drugs involved. So what can be done if a ... professor Jean-Christophe Leroux from the Institute of Pharmaceutical Sciences at ... "The task was to develop an agent that could eliminate ...
    (Date:10/16/2014)... new synthesis of recent research findings to inform their ... two states. , The Ecology and Management of ... Synthesis of the Relevant Biophysical Science and Implications for ... the U.S. Forest Service,s Pacific Northwest Research Station, is ... a synthesis of the large body of scientific information ...
    Breaking Biology News(10 mins):Emergency aid for overdoses 2Emergency aid for overdoses 3New report synthesizes best available science on management of moist mixed-conifer forests 2
    ... cells can grow new extensions when the amount of three ... , The research examined three related receptor proteins, called ... of rats. , When researchers increased the amount ... up to three times longer than those on nerve cells ...
    ... the detrimental loss of sea ice sheets in ... the scientific community have been saying for years. Now ... of Earth and Environmental Science are turning their attention to ... having similar effects in the frigid Antarctic region. ...
    ... tumor cells implanted in mice have shown that the ... breast cancer to the lungs. The new studies by ... genes work together to promote the growth of primary ... cancerous cells to escape into the bloodstream and penetrate ...
    Cached Biology News:3 proteins may play important role in nerve-cell repair 2UTSA researchers examine effects of global warming on Antarctic 2A genetic 'gang of 4' drives spread of breast cancer 2A genetic 'gang of 4' drives spread of breast cancer 3A genetic 'gang of 4' drives spread of breast cancer 4
    ... The product contains 5 ... coated with the monoclonal BerEP4 ... EpCAM (epithelial cell adhesion molecule). ... samples of 2 x 10e7 ...
    MOUSE ANTI HUMAN FACTOR I...
    Superior homology search software - in all the flavours of blast, with increased sensitivity and speed. Free windows version for academic use....
    GFX PCR DNA,Gel Band Purif,100, 1 EA. Category: Nucleotide Sample Handling....
    Biology Products: